10 Most Undervalued Pharma Stocks to Buy Now

5. AstraZeneca PLC (NASDAQ:AZN)

P/E Ratio: 13.94

AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company headquartered in Cambridge, UK, operates in over 130 countries with more than 80,000 employees. Formed in 1999 through the merger of Astra AB and Zeneca Group, the company is a leader in oncology, rare diseases, and biopharmaceuticals, with R&D hubs in Cambridge (UK), Gothenburg (Sweden), and Gaithersburg (US).

A major recent milestone for the company is the U.S. FDA approval of Datroway (datopotamab deruxtecan) for patients with EGFR-mutated, previously treated non-small cell lung cancer (NSCLC). Datroway is the first TROP2-directed antibody-drug conjugate approved for this indication and offers improved progression-free and overall survival compared to chemotherapy, based on results from the Phase III TROPION-Lung01 trial. The drug was co-developed with Daiichi Sankyo, showcasing AstraZeneca PLC (NASDAQ:AZN)’s focus on collaborative innovation.

This approval strengthens the company’s extensive oncology portfolio, which includes Tagrisso, Imfinzi, and Enhertu, and supports its leadership in targeted cancer therapies.

Beyond lung cancer, AZN is advancing treatments across other cancers. The SERENA-6 trial showed positive Phase III results for camizestrant, an oral SERD for HR-positive breast cancer, while the MATTERHORN trial reported promising data for Imfinzi in early-stage gastric and gastroesophageal junction cancers.

AstraZeneca PLC (NASDAQ:AZN) continues to drive global oncology research, regularly presenting plenary data at leading medical conferences like ASCO, reflecting its position at the forefront of cancer innovation.